Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov 7:7:20-22.
doi: 10.1016/j.jdcr.2020.10.024. eCollection 2021 Jan.

Onychodystrophy associated with dupilumab therapy for atopic dermatitis

Amanda E Zubek  1 , Matthew D Vesely  1
Affiliations
Case Reports

Onychodystrophy associated with dupilumab therapy for atopic dermatitis

Amanda E Zubek et al. JAAD Case Rep. .
No abstract available

Keywords: AD, atopic dermatitis; IL, interleukin; atopic dermatitis; dupilumab; eczematous nails; nail dystrophy; onychodystrophy.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Nail changes in a patient with AD treated with dupilumab. Three months after starting the dupilumab therapy, the patient presented with hyperkeratosis of the nail bed and hyponychium, scaling of the lateral nail folds and eponychium with loss of adhesion of the cuticle to the nail plate, and bilateral distal and lateral onycholysis. A, On the right thumb, koilonychia, onychorrhexis, and irregular longitudinal nail plate fracturing were observed, while the left nail exhibited multiple horizontal depressions (Beau's lines), a median longitudinal groove, and a mid-nail transverse split. B, After 6 months of the continued dupilumab therapy, both the thumbnails improved and showed longitudinal ridging, improving distal nail dystrophy, and less prominent horizontal ridging. C, After 15 months of the continued dupilumab therapy, nail regrowth, with evidence of chronic paronychia and mild transverse ridges, mild longitudinal ridging, and nail pits were observed. AD, Atopic dermatitis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Weidinger S., Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122. - PubMed
    1. Simpson E.L., Bieber T., Guttman-Yassky E. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. - PubMed
    1. Soria A., Du-Thanh A., Seneschal J., Jachiet M., Staumont-Sallé D., Barbarot S. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312–1315. - PMC - PubMed
    1. Chng W.Q., Yew Y.W. Nail manifestations in atopic dermatitis: a systematic review. Int J Dermatol. 2020;59(6):670–676. - PubMed
    1. Chung B.Y., Choi Y.W., Kim H.O., Park C.W. Nail dystrophy in patients with atopic dermatitis and its association with disease severity. Ann Dermatol. 2019;31(2):121–126. - PMC - PubMed

Publication types

LinkOut - more resources